Significant effects of mild endogenous hormonal changes in humans: considerations for low-dose testing.

Abstract

We review the significant and adverse health effects that can occur with relatively small endogenous hormonal changes in pubertal and adult humans. We discuss the effects of hormonal changes that occur within normal physiologic ranges--such as the rising levels of estrogen in peripuberty, which cause growth spurts at low levels and then the fusion of epiphyses at higher levels--and the hormonal variations during the menstrual cycle and their relation to genital phenotypic changes and intercurrent disease evolution. We turn next to adaptive changes in gonadal and other functions during aging, exercise, stress, starvation, and chronic diseases, which can serve as models for the effects of exogenous, hormonally active compounds. Then we review the states of borderline hormonal imbalances such as subclinical (having few or very mild symptoms, if any) hypothyroidism or hyperthyroidism, glucose intolerance, and other endocrine conditions. Finally, we review the deleterious systemic effects of gonadal imbalance. Information stemming from clinical observations leads to the concept of "no threshold" within the endocrine system and thus illustrates the importance of considering low-dose testing for chemicals that interfere with hormonal activity. We also urge attention to more sensitive, less visible end points such as osteoporosis, increased risk for cardiovascular disease, or cognitive changes.

Low Doses of Bisphenol A Promote Human Seminoma Cell Proliferation by Activating PKA and PKG via a Membrane G-Protein–Coupled Estrogen Receptor

“…When mixed together at this low concentration, BPA and E 2 are mutually antagonistic, whereas DES, also a potent ligand for nuclear ER, at this low concentration only moderately counteracts the nongenomic BPA effect, possibly for conformational reason. Our model illustrates the paradoxical inversed U-shaped curve, explaining effects at very low doses ( Brucker-Davis et al 2001 ), that has been described for BPA in several models ( Maffini et al 2006 ; vom Saal and Hughes 2005 ; Welshons et al 2006 ), which could be produced by two different ERs and two different, genomic and non-genomic, mechanisms.…”

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

“…(d) occurring at a dose administered to an animal that produces blood concentrations of that chemical in the range of what has been measured in the general human population (i.e. not exposed occupationally, and often referred to as an environmentally relevant dose because it creates an internal dose relevant to concentrations of the chemical measured in humans) ( 34 , 35 ).…”

Xenoestrogen-Induced ERK-1 and ERK-2 Activation via Multiple Membrane-Initiated Signaling Pathways

“…Possible reasons for these potent effects not being noted previously are that little testing of the nongenomic pathway has been done, many tests did not examine such low concentrations, and some test conditions probably did not adequately remove endogenous estrogen levels (as we have done by use of low quantities of extensively charcoal-stripped serum) to reveal effects of these low concentrations. The potent effects we see on nongenomic signaling mechanisms could explain why concentrations previously determined to be inactive via genomic mechanisms still have toxic and teratogenic effects on wildlife ( Brucker-Davis et al 2001 ). Therefore, the threat levels of these compounds to wildlife, and probably humans, need to be reconsidered.…”